304 Views
Original Research
Presentation Type: Virtual Poster
Session: Section on Advances in Therapeutics and Technology Program
Stephen G. Kaler, MD, MPH
Principal Investigator, Center for Gene Therapy
Nationwide Children’s Hospital
The Ohio State University School of Medicine
Columbus, Ohio
Disclosure: No Financial Relationships Disclosed
Shama Munim, MS
Director, Regulatory Affairs
Cyprium Therapeutics
New York, New York
Disclosure: Cyprium Therapeutics (Products/Services: Director, Regulatory Affairs) (Employee)Fortress Biotech (Products/Services: Director, Regulatory Affairs) (Employee)
Michael Chen, PhD
Statistician
Cyprium Therapeutics
Berkley Heights, New Jersey
Disclosure: Cyprium Therapeutics (Products/Services: Consultant for Biostatistics) (Consultant)TG Therapeutics (Products/Services: Consultant in Biostatistics) (Consultant)
Robert Niecestro, PhD
Head of Regulatory Affairs
Cyprium Therapeutics
New York, New York
Disclosure: Aspargo Labs (Products/Services: Consultant for clinical-regulatory development) (Consultant, Stockholder/Ownership Interest (excluding diversified mutual funds))Cyprium Therapeutics (Products/Services: Consultant NDA Preparation) (Consultant)
Lung S. Yam, MD, PhD
CEO
Cyprium Therapeutics
New York, New York
Disclosure: Cyprium Therapeutics (Products/Services: Executive and employee; shareholder) (Employee, Stockholder/Ownership Interest (excluding diversified mutual funds))Fortress Biotech (Products/Services: Shareholder;) (Stockholder/Ownership Interest (excluding diversified mutual funds))TG Therapeutics (Products/Services: Shareholder) (Stockholder/Ownership Interest (excluding diversified mutual funds))